Pfizer Inc Stock Current Valuation
| PFE Stock | USD 25.42 0.27 1.05% |
Valuation analysis of Pfizer Inc helps investors to measure Pfizer's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 240.8 B, whereas Enterprise Value Over EBITDA is forecasted to decline to 14.99. Fundamental drivers impacting Pfizer's valuation include:
Price Book 1.6451 | Enterprise Value 208 B | Enterprise Value Ebitda 21.4072 | Price Sales 2.5033 | Forward PE 11.6686 |
Undervalued
Today
Please note that Pfizer's price fluctuation is very steady at this time. Calculation of the real value of Pfizer Inc is based on 3 months time horizon. Increasing Pfizer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Pfizer Inc is useful when determining the fair value of the Pfizer stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Pfizer. Since Pfizer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pfizer Stock. However, Pfizer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.42 | Real 32.41 | Target 38.67 | Hype 25.42 | Naive 24.79 |
The real value of Pfizer Stock, also known as its intrinsic value, is the underlying worth of Pfizer Inc Company, which is reflected in its stock price. It is based on Pfizer's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Pfizer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pfizer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pfizer Inc helps investors to forecast how Pfizer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pfizer more accurately as focusing exclusively on Pfizer's fundamentals will not take into account other important factors: Pfizer Inc Company Current Valuation Analysis
Pfizer's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pfizer Current Valuation | 207.98 B |
Most of Pfizer's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pfizer Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Pfizer is extremely important. It helps to project a fair market value of Pfizer Stock properly, considering its historical fundamentals such as Current Valuation. Since Pfizer's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pfizer's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pfizer's interrelated accounts and indicators.
Click cells to compare fundamentals
Pfizer Current Valuation Historical Pattern
Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pfizer current valuation as a starting point in their analysis.
Pfizer Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pfizer Inc has a Current Valuation of 207.98 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
Pfizer Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in current valuation category among related companies.
Pfizer ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Pfizer Fundamentals
| Return On Equity | 0.0235 | ||||
| Return On Asset | 0.0155 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | (0.50) % | ||||
| Current Valuation | 207.98 B | ||||
| Shares Outstanding | 5.66 B | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 69.93 % | ||||
| Number Of Shares Shorted | 65 M | ||||
| Price To Earning | 9.48 X | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 2.50 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B | ||||
| EBITDA | 10.53 B | ||||
| Net Income | 2.13 B | ||||
| Cash And Equivalents | 2.85 B | ||||
| Cash Per Share | 6.44 X | ||||
| Total Debt | 75.04 B | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.59 X | ||||
| Book Value Per Share | 15.77 X | ||||
| Cash Flow From Operations | 8.7 B | ||||
| Short Ratio | 1.40 X | ||||
| Earnings Per Share | 0.37 X | ||||
| Price To Earnings To Growth | 0.26 X | ||||
| Target Price | 31.1 | ||||
| Number Of Employees | 88 K | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 145.47 B | ||||
| Total Asset | 226.5 B | ||||
| Retained Earnings | 118.35 B | ||||
| Working Capital | (4.46 B) | ||||
| Current Asset | 43.8 B | ||||
| Current Liabilities | 29.4 B | ||||
| Annual Yield | 0.07 % | ||||
| Five Year Return | 3.60 % | ||||
| Net Asset | 226.5 B | ||||
| Last Dividend Paid | 1.64 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pfizer Piotroski F Score and Pfizer Altman Z Score analysis. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.